Seattle Genetics (SGEN), Agensys Present Updated ASG-22ME, ASG-15ME Data at ESMO 2016
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/18/2024
- Stocks decline as interest rate uncertainty, earnings weigh
- ASML slides as Q1 sales fall short but firm still on track for 2025 revenue target
- US dollar weakens as market consolidates gains, but uptrend intact
- Abbott Laboratories (ABT) narrows 2024 earnings guidance, shares slip
- Stocks have priced in much of the 2024 optimism - Wells Fargo
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- ICZOOM Group (IZM) Discloses Request to Withdraw Registration Statement on Form F-1
- Alaska Airlines flights resume after being grounded over aircraft system issue
- Crude Inventory Rose 2.7 Million Barrels Last Week, Says EIA
- Lithium Americas Corp (LAC) Announces Proposed 55M Share Offering
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- After-hours movers: United Airlines, J.B. Hunt, and more
- Midday movers: Morgan Stanley, UnitedHealth rise; Tesla falls
- Morgan Stanley, UnitedHealth and Bank of America rise premarket; Tesla falls
Seattle Genetics and Agensys, an Affiliate of Astellas, Highlight Promising Enfortumab Vedotin (ASG-22ME) and ASG-15ME Phase 1 Data in Metastatic Urothelial Cancer at 2016 ESMO Congress
October 7, 2016 9:00 AM EDT-Objective Response Rates Presented for Both Antibody-Drug Conjugate Programs-
-Enfortumab Vedotin Demonstrates 59 Percent Objective Response Rate at Recommended Phase 2 Dose of 1.25 mg/kg, Supporting Advancement of the Development Program-
BOTHELL, Wash. & NORTHBROOK, Ill.--(BUSINESS WIRE)-- Seattle Genetics, Inc. (NASDAQ: SGEN) and Agensys, an affiliate of Astellas, today presented updated clinical data... More
